Cost-effectiveness of licensed treatment options for restless legs syndrome in the UK and Sweden

2008 ◽  
Vol 24 (10) ◽  
pp. 2919-2930 ◽  
Author(s):  
M. Lees ◽  
G. Roberts ◽  
M. Tabberer ◽  
R. DasGupta ◽  
H. W. Finnern ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Restless Legs Syndrome ◽  
Treatment Options ◽  
Restless Legs ◽  
The Uk

Treatment Options in Intractable Restless Legs Syndrome/Willis-Ekbom Disease (RLS/WED)

2016 ◽  
Vol 18 (2) ◽  
Author(s):  
Fabrizio Rinaldi ◽  
Andrea Galbiati ◽  
Sara Marelli ◽  
Luigi Ferini Strambi ◽  
Marco Zucconi
Keyword(s):  
Restless Legs Syndrome ◽  
Treatment Options ◽  
Restless Legs

PNL14 THE COST-EFFECTIVENESS OF TREATING PATIENTS WITH RESTLESS LEGS SYNDROME (RLS) USING ROPINIROLE

2004 ◽  
Vol 7 (6) ◽  
pp. 791 ◽  
Author(s):  
AP Moore ◽  
A Lloyd ◽  
DA Scott ◽  
M Connolly ◽  
S Dixon
Keyword(s):  
Cost Effectiveness ◽  
Restless Legs Syndrome ◽  
Restless Legs ◽  
The Cost

scholarly journals Clinical correlates of the restless legs syndrome

2012 ◽  
Vol 70 (7) ◽  
pp. 529-531 ◽  
Author(s):  
Luis Fabiano Marin ◽  
Andre Carvalho Felicio ◽  
William Adolfo Santos ◽  
Lucila Bizari Prado ◽  
Gilmar Fernandes Prado
Keyword(s):  
Restless Legs Syndrome ◽  
Treatment Options ◽  
Disease Onset ◽  
Epidemiological Studies ◽  
Deficiency Anemia ◽  
Clinical Correlates ◽  
Restless Legs ◽  
Male Sex ◽  
Stage Renal Disease ◽  
End Stage

OBJECTIVE: To determine the clinical correlates of the restless legs syndrome (RLS) in a Brazilian sleep disorders center. METHODS: We retrospectively studied 118 patients with RLS from January, 2004, to December, 2010. The analyzed variables were: age at disease onset, gender, race, years of school instruction, primary and secondary RLS, and treatment options. RESULTS: Among the studied patients, 83.9% were women with a female/male sex ratio of 5:1. Mean age of the patients at symptom onset ± standard deviation was 41.7±17.9 years-old. The primary RLS was found in 85% of patients. The other 15% remainders consisted of secondary forms, and they were associated with neuropathy, iron deficiency anemia, end-stage renal disease, or Parkinson's disease. Drug therapy for RLS was introduced in 67% of patients. CONCLUSIONS: Most patients presented primary RLS with an early disease onset. Further epidemiological studies are welcomed to provide better information on secondary RLS in Brazil.

Restless legs syndrome?new insights into clinical characteristics, pathophysiology, and treatment options

2004 ◽  
Vol 251 (S6) ◽  
Author(s):  
K. Stiasny-Kolster ◽  
C. Trenkwalder ◽  
W. Fogel ◽  
W. Greulich ◽  
M. Hahne ◽  
...  
Keyword(s):  
Restless Legs Syndrome ◽  
Clinical Characteristics ◽  
Treatment Options ◽  
Restless Legs

scholarly journals Epidemiology, impact, and treatment options of restless legs syndrome in end-stage renal disease patients: an evidence-based review

2014 ◽  
Vol 85 (6) ◽  
pp. 1275-1282 ◽  
Author(s):  
Christoforos D. Giannaki ◽  
Georgios M. Hadjigeorgiou ◽  
Christina Karatzaferi ◽  
Marios C. Pantzaris ◽  
Ioannis Stefanidis ◽  
...  
Keyword(s):  
Renal Disease ◽  
Restless Legs Syndrome ◽  
End Stage Renal Disease ◽  
Treatment Options ◽  
Evidence Based ◽  
Restless Legs ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Treatment Options for Idiopathic Restless Legs Syndrome

2015 ◽  
Vol 10 (01) ◽  
pp. 45 ◽  
Author(s):  
Félix Javier Jiménez-Jiménez ◽  
Hortensia Alonso-Navarro ◽  
Elena García-Martín ◽  
José AG Agúndez ◽  
◽  
...  
Keyword(s):  
Restless Legs Syndrome ◽  
Dopamine Agonists ◽  
Treatment Options ◽  
Drug Group ◽  
First Line ◽  
Preliminary Results ◽  
Restless Legs ◽  
Exponential Increase ◽  
Alternative Drug ◽  
Drug Treatments

The emergence of new effective therapies for idiopathic restless legs syndrome (iRLS) or Willis–Ekbom disease (WED) during the last 15 years resulted in an exponential increase of reports regarding this syndrome and, especially, treatment options. In this review, we summarise the main findings related to neuropharmacological aspects and non-pharmacological therapies of idiopathic RLS (iRLS). As was previously reported in several guidelines, dopamine agonists (fundamentally nonergotic derivatives), gabapentin and pregabalin should be considered as first-line therapies, as well as opiates as an alternative drug group. Preliminary results suggest that several non-pharmacological therapies should be promising as alternatives or adjuvants to drug treatments.

Sign in / Sign up

Export Citation Format

Share Document